Synthesis and characterization of gadolinium-Peptidomimetic complex as an αvβ3 integrin targeted MR contrast agent.
暂无分享,去创建一个
M. Brechbiel | J. Frank | B. Lewis | D. Milenic | K. Baidoo | Yang Zhou | Young-Seung Kim | Henry Bryant
[1] Yongmin Chang,et al. Improved tumor-targeting MRI contrast agents: Gd(DOTA) conjugates of a cycloalkane-based RGD peptide. , 2014, Biochemical and biophysical research communications.
[2] E. A. Waters,et al. Synthesis and characterization of a porphyrazine-Gd(III) MRI contrast agent and in vivo imaging of a breast cancer xenograft model. , 2014, Contrast media & molecular imaging.
[3] M. Brechbiel,et al. Synthesis and characterization of αvβ₃-targeting peptidomimetic chelate conjugates for PET and SPECT imaging. , 2012, Bioorganic & medicinal chemistry letters.
[4] S. Durell,et al. Programmable Multivalent Display of Receptor Ligands using Peptide Nucleic Acid Nanoscaffolds , 2012, Nature Communications.
[5] Ambika Bumb,et al. Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. , 2010, Chemical reviews.
[6] Jae-Chang Jung,et al. Gd‐DOTA Conjugate of RGD as a Potential Tumor‐Targeting MRI Contrast Agent , 2008, Chembiochem : a European journal of chemical biology.
[7] T. Meade,et al. Synthesis of multimeric MR contrast agents for cellular imaging. , 2008, Journal of the American Chemical Society.
[8] Peter Caravan,et al. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. , 2006, Chemical Society reviews.
[9] Zhimin Shen,et al. Synthesis, in vitro, and in vivo characterization of an integrin αvβ3-targeted molecular probe for optical imaging of tumor , 2005 .
[10] Heather Kalish,et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. , 2004, Blood.
[11] Xiaoping Hu,et al. Advances in high-field magnetic resonance imaging. , 2004, Annual review of biomedical engineering.
[12] G. Gillespie,et al. Human Malignant Glioma Therapy Using Anti-αVβ3 Integrin Agents , 2004, Journal of Neuro-Oncology.
[13] D. Piwnica-Worms,et al. Synthesis and characterization of a Gd-DOTA-D-permeation peptide for magnetic resonance relaxation enhancement of intracellular targets. , 2003, Molecular imaging.
[14] Junichi Takagi,et al. Integrin activation and structural rearrangement , 2002, Immunological reviews.
[15] M. Bednarski,et al. Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.
[16] Sibylle Ziegler,et al. Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .
[17] M Schwaiger,et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] Stasia A. Anderson,et al. Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles , 2000 .
[19] M. Schaar,et al. Evaluation of a radiolabelled cyclic DTPA‐RGD analogue for tumour imaging and radionuclide therapy , 2000, International journal of cancer.
[20] R. Lauffer,et al. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.
[21] D. Cheresh,et al. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. , 1992, The Journal of clinical investigation.
[22] D. Cheresh,et al. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. , 1991, The Journal of clinical investigation.
[23] D. Elder,et al. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. , 1990, Cancer research.